Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus

Infection Control and Hospital Epidemiology

Volumn 28, Issue 6, 2007, Pages 695-701

  Luque, Amneris ^a,d   Hulse, S ^a   Wang, D ^a   Shahzad, U ^a,c   Tanzman, E ^b   Antenozzi, S ^b   Smith, B ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE TRANSMISSION; FATIGUE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NAUSEA; OCCUPATIONAL EXPOSURE; PROPHYLAXIS; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADENINE; ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH SERVICES; PATIENT COMPLIANCE; PHOSPHONIC ACIDS; PUBLIC HEALTH ADMINISTRATION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; STUDENT HEALTH SERVICES; UNIVERSITIES; ZIDOVUDINE;

EID: 34250700917     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/518349     Document Type: Article

References (17)

1. US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50(RR-11):1-42.
2. DeGruttola V, Seage GR III, Mayer KH, et al. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42:849-856.
3. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002; 29:38-43.
4. European Study Group. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992; 304:809-813.
5. Page-Shafer K, Shiboski CH, Osmond DH, et al. Risk of HIV attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002; 16:2350-2352.
6. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:175-176.
7. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom and United States, January 1988-August 1994. MMWR 1995; 44:929-933.
8. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-1490.
9. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
10. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771-9775.
11. Tsai CC, Emau P, Follis KE, et al. Effectiveness of post-inoculation R-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
12. Teixeira Garcia M, Morales Figueiredo R, Moretti ML, et al. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis 2005; 32:214-219.
13. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54(RR-2):1-20.
14. New York State Department of Health AIDS Institute. HIV Prophylaxis Following Non-Occupational Exposure Including Sexual Assault. New York: New York State Department of Health; 2004. Available at: http://www.hivguidelines. org/. Accessed April 20, 2006.
15. Balzarini J, Hao Z, Herdewijn P, et al. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci 1991; 88:1499-1503.
16. Kearny BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43:595-612.
17. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.